Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 9/20 | 0.60 |
| ▸ | MAOB | P27338 | 10/20 | 0.54 |
| ▸ | MAOA | P21397 | 4/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.54 |
| ▸ | SDHA | P31040 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CALML3 | P27482 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3117922 | 0.89 | MAOB (0.68) | F10MAOBMAOAPTGS1SDHA | |
| SCHEMBL3698286 | 0.89 | MAOB (0.68) | F10MAOBMAOAPTGS1SDHA | |
| SCHEMBL30549098 | 0.89 | MAOB (0.68) | F10MAOBMAOAPTGS1SDHA | |
| SCHEMBL5105138 | 0.89 | MAOB (0.55) | F10MAOBMAOAPTGS1SDHA | |
| SCHEMBL5105135 | 0.89 | MAOB (0.55) | F10MAOBMAOAPTGS1SDHA | |
| SCHEMBL28426964 | 0.87 | MAOB (0.55) | F10MAOBMAOAPTGS1SDHA | |
| SCHEMBL28426963 | 0.87 | MAOB (0.55) | F10MAOBMAOAPTGS1SDHA | |
| SCHEMBL18397561 | 0.86 | MAOB (0.61) | F10MAOBMAOAPTGS1SDHA | |
| SCHEMBL20296082 | 0.86 | MAOB (0.61) | F10MAOBMAOAPTGS1SDHA | |
| SCHEMBL6629866 | 0.86 | F10 (0.65) | F10MAOBMAOAPTGS1SDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730154-B1 | RIFAMYCIN DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES | CUMBRE IP VENTURES L P (US) | 2012-10-17 | — | — | EP | disclosed |
| US-7247634-B2 | Rifamycin derivatives effective against drug-resistant microbes | CUMBRE PHARMACEUTICALS INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1730154-A2 | RIFAMYCIN DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES | Cumbre Pharmaceuticals Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20050261262-A1 | Rifamycin derivatives effective against drug-resistant microbes | CUMBRE INC. (US) | 2005-11-24 | — | — | US | disclosed |
| WO-2005070940-A2 | RIFAMYCIN DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES | CUMBRE PHARMACEUTICALS INC. (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261262-A1 | Rifamycin derivatives effective against drug-resistant microbes | RIF1, MRPL37, AURKAIP1 | F10 3771/4885MAOB 2321/4885MAOA 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.